About us
PDC*line Pharma is a clinical-stage Biotechnology company that develops a new class of potent, off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma reported promising Phase I/II results in lung cancer (PDC*lung) in 2024. Preparations are now underway for a randomized Phase IIb trial in lung cancer, and a Phase Ib trial in colorectal cancer with neoantigens (PDC*neo). The company has raised €61M in equity and non-dilutive funding and signed a €108M licensing deal in Asia with the Korean pharmaceutical company, LG Chem Life Science.
PDC*line Pharma comprises a team of 42 highly skilled professionals based in Liège (Belgium) and Grenoble (France).
Key Achievements:
In January 2019, PDC*line Pharma has been GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control & Release Activities for PDC*lung, a drug for lung cancer immunotherapy.
In March 2019, PDC*line Pharma granted exclusive license in South Korea and exclusive option in other Asian countriesto LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer. The total deal value is €108M (123M$) plus significant tiered royalties on net sales in Asia.
In May and June 2019, PDC*line Pharma obtains authorization to launch phase I/II trial of its cancer vaccine (PDC*lung01) in non-small-cell lung cancer from the Belgium and French Authorities respectively. Regulatory Authorities authorized the initiation of an open-label, dose-escalation, phase I/II trial with the cancer vaccine candidate for non-small-cell lung cancer.
In December 2019, PDC*line Pharma raises €20M in Series B1 financing round. Five new investors joined the round of financing: Korean Investment Partners, the leading multi-billion dollar South-Korean fund, two further South-Korean funds, Shinhan-Cognitive Start-up Fund and UTC 2019 BIOVENTUREFUND, as well as two Belgian funds, SRIW (The Regional Investment Company of Wallonia) and Sambrinvest (the investment fund of Charleroi).
In February 2020, the first patient with non-small cell lung cancer has been dosed with PDC*lung01.
In December 2021, PDC*line Pharma raises €17,5M€ in Series B2 financing round. This financing round, led by Korea Investment Partners, a leading multi-billion dollar South-Korean fund, also involved a syndicate of new South-Korean investors in life sciences: Alpha Holdings, Brain Asset Management and Hansongneotech Co. Ltd.
In December 2022: PDC*line Pharma reaches 90% success rate for the release of the 11 clinical batches of PDC*lung01 manufactured for the Phase I/II trial.
In September, December 2022 and February 2023: Presentation of first immunological and clinical results of the first three cohorts of patients treated with PDC*lung (in combination or not with an antiPD-1) in three prestigious conferences in Medical Oncology (ESMO, ESMO-IO and CIMT).
In June 2023, PDC*line Pharma relocates its headquarter in a brand-new facility in Liège (Belgium) including a 330m2 GMP manufacturing Unit.
In October 2023, completion of patient enrolment with non-small cell lung cancer in the phase I/II clinical trial (inclusion of the last patient in the last cohort).
In January 2024, PDC*line Pharma and partners receive €8.1M additional grant from the Walloon region to develop PDC*neo for colorectal cancer.
In April 2024, PDC*line Pharma is selected for an oral presentation of its promising interim results with PDC*lung01 at the AACR annual conference.
In December 2024, PDC*line Pharma is selected for an oral presentation of its promising primary results with PDC*lung01 at the ESMO-IO annual conference.
See enclosed the updated PDC*line Pharma company leaflet (English version)
See enclosed the updated PDC*line Pharma company leaflet (Korean version)
See enclosed the updated PDC*line Pharma company leaflet (French version)
Unique advantages
PDC*line offers unique advantages over conventional cancer vaccines:
1. PDC*line is a professional antigen-presenting cell, much more potent than conventional cancer vaccines in priming and expanding antitumor-specific cytotoxic T cells.
2. PDC*vac can easily be produced on a large scale, with a fully mastered and simple manufacturing process (use of bioreactors; no need for growth, differentiation or activation factors; storage for years).
3. PDC*vac is easy to use: the off-the-shelf product in its ready-to use formulation is thawed and injected to treat any patient with a cancer type expressing the target antigens.
4. PDC*vac technology is very versatile: tumor antigens could be provided by simple peptide pulsing (currently used) , mRNA transfection or retrovirus transduction of PDC*line; the target population can be extended beyond HLA-A2 (currently used) by using other HLA already expressed by PDC*line, or added by genetic modification.
5. PDC*vac synergizes with anti-PD-1 to boost antitumor CD8+ T cells.
In addition, the safety of PDC*vac and its ability to prime and boost antitumor T cells in vivo have already been demonstrated in humanized mice and in more than 75 melanoma and lung-cancer patients.
PDC*line Pharma develops innovative and potent therapeutic cancer vaccines which overcome the challenges encountered by earlier cancer-vaccine strategies. The objective of PDC*line Pharma is to demonstrate in a randomised study that its innovative approach can prime and boost CD8+ T cells' antitumor immunity in lung-cancer patients and enhance clinical response to anti-PD-1.
